← Back to Portfolio

SFJ X (PhaseBio)

SFJ X is supporting a clinical co-development deal with PhaseBio (NASDAQ: PHAS) to fund and manage clinical development of PB2452 which is an antidote to Brilinta, an oral anti-platelet medicine manufactured by AstraZeneca. Reversal of this anti-clotting activity is needed to reduce the risk of bleeding in high risk situations such as trauma or surgery.
LocationPleasanton, CA
CEORobert DeBenedetto
Partner Kurt von Emster